VTv Therapeutics advances its promising oral treatment for type 1 diabetes, cadisegliatin, as it prepares for key expert discussions and data release, while market caution remains due to the company’s ongoing losses and long regulatory journey.
vTv Therapeutics said on August 6 that it is moving ahead with cadisegliatin, its experimental oral treatment for type 1 diabetes, and plans to discuss clinical data with outside medical experts in the fourth quarter. The programme centres on hypoglycaemia management, a persistent and potentially dangerous problem for people with type 1 diabetes, and the company is positioning the drug as an add-on to insulin rather than a replacement.
The latest update extends a year of progress for the late-stage biotech. In March, vTv said the US Food and Drug Administration had lifted a clinical hold on the cadisegliatin programme after earlier concerns over a laboratory finding, allowing the company to proceed with its Phase 3 work. By May, it had resumed screening in the CATT1 study after shortening the trial from 12 months to 6 months in an effort to speed data collection. The company said at the time that topline results were still expected in the second half of 2026.
In August 2025, vTv announced that the first participant had been randomised in CATT1, a key step in testing cadisegliatin as an adjunct to insulin. Chief medical officer Thomas Strack said then that the study could help improve glycaemic control, while chief executive Paul Sekhri has repeatedly cast the drug as a potentially important advance for diabetes care. The company says cadisegliatin is a liver-selective glucokinase activator that has already been studied in more than 500 subjects and appeared to be well tolerated for periods of up to six months.
Investors, however, are still dealing with the realities of an unprofitable drug developer. GuruFocus said vTv’s price-to-sales ratio stood at 13.66, well below its historical median of about 56.1 times, which suggests the market is still cautious despite the recent clinical progress. The company’s GF Score was 28 out of 100, reflecting strong financial strength but weak profitability and momentum. It also pointed to an Altman Z-score of 6.42 and a current ratio of 14.36, signs of solid liquidity even as losses continue.
That leaves vTv as a classic binary biotech story: a company with a promising asset, a long regulatory path and valuation that will depend heavily on clinical readouts. The upcoming expert discussions and second-half data release are likely to be watched closely for clues on whether cadisegliatin can move from a speculative programme to a credible commercial prospect.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
